Since new therapies for lupus have been extremely slow to develop and lupus patients have a great unmet medical need, an independent pharma-external effort has been undertaken to evaluate all FDA approved drugs for potential use in this autoimmune disease. In 2013, literature mining evaluated the >1000 compounds approved by the FDA and identified 157 possible lupus therapies. These were ranked using an evidence-based Composite Lupus Treatment Scoring (CoLTs) approach (Lupus 25:1150, 2016). Between 2014-2017, the FDA has approved 125 new drugs, seven of which targeted an autoimmune/inflammatory disease and none of which was approved for use in SLE. These drugs were evaluated for possible utility in autoimmune diseases and 43 were identified as possible therapies and ranked by the CoLT-scoring system. Nine were identified as high-priority candidates for repositioning into lupus including drugs targeting cellular metabolism, kinases and the immune system. In addition, potential utility of drug candidates in SLE was gauged by bioinformatic analysis of gene expression profiles from lupus tissues (kidney, skin, synovium) and the periphery (Whole Blood, B cells, T cells, myeloid cells). Connectivity scoring with gene expression profiles available in the Library of Integrated Network Cellular Signatures (LINCS) confirmed many of the drug candidates and also suggested some unique potential drug therapies. The combination of literature mining and bioinformatic analysis of gene expression profiles has yielded a group of high priority candidates that have promise as therapies for SLE.